Genetic Variants of CBR3 Reduce Anthracycline Metabolism
763
Two allelic variants of aldo-ketoreductase 1A1 exhibit reduced in vitro metabolism
of daunorubicin. Drug Metab Dispos 36:904–910.
Barry E, Alvarez JA, Scully RE, Miller TL, and Lipshultz SE (2007) Anthracycline-
induced cardiotoxicity: course, pathophysiology, prevention and management. Ex-
pert Opin Pharmacother 8:1039–1058.
Blanco JG, Leisenring WM, Gonzalez-Covarrubias VM, Kawashima TI, Davies SM,
Relling MV, Robison LL, Sklar CA, Stovall M, and Bhatia S (2008) Genetic
polymorphisms in carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone
oxidoreductase 1 gene NQO1 in patients who developed anthracycline-related
congestive heart failure after childhood cancer. Cancer 112:2789–2795.
Cort e´ s-Funes H and Coronado C (2007) Role of anthracyclines in the era of targeted
therapy. Cardiovasc Toxicol 7:56–60.
Danesi R, Fogli S, Gennari A, Conte P, and Del Tacca M (2002) Pharmacokinetic
pharmacodynamic relationships of the anthracycline anticancer drugs. Clin Phar-
macokinet 41:431–444.
J o¨ rnvall H, Persson B, Krook M, Atrian S, Gonz a` lez-Duarte R, Jeffery J, and Ghosh
D (1995) Short-chain dehydrogenases/reductases (SDR). Biochemistry 34:6003–
6013.
Kassner N, Huse K, Martin HJ, G o¨ dtel-Armbrust U, Metzger A, Meineke I, Brock-
m o¨ ller J, Klein K, Zanger UM, Maser E, et al. (2008) Carbonyl reductase 1 is a
predominant doxorubicin reductase in the human liver. Drug Metab Dispos 36:
2113–2120.
Lakhman SS, Ghosh D, and Blanco JG (2005) Functional significance of natural
allelic variant of human carbonyl reductase 3 (CBR3). Drug Metab Dispos 33:254–
257.
Licata S, Saponiero A, Mordente A, and Minotti G (2000) Doxorubicin metabolism
and toxicity in human myocardium: role of cytoplasmic deglycosidation and car-
bonyl reduction. Chem Res Toxicol 13:414–420.
Lipp HP and Bokemeyer C (1999) Anthracyclines and other intercalating agents, in
Anticancer Drug Toxicity: Prevention, Management and Clinical Pharmacokinetics
(Lipp HP ed) pp 81–113, Marcel Dekker, New York.
Matsunaga T, Shintani S, and Hara A (2006) Multiplicity of mammalian reductases
for xenobiotic carbonyl compounds. Drug Metab Pharmacokinet 21:1–18.
Menna P, Recalcati S, Cairo G, and Minotti G (2007) An introduction to the metabolic
determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol 7:80–85.
Miura T, Nishinaka T, and Terada T (2008) Different functions between human
monomeric carbonyl reductase 3 and carbonyl reductase 1. Mol Cell Biochem
315:113–121.
Deng S and Wojnowski L (2007) Genotyping the risk of anthracycline-induced
cardiotoxicity. Cardiovasc Toxicol 7:129–134.
El-Hawari Y, Favia AD, Pilka ES, Kisiela M, Oppermann U, Martin HJ, and Maser
E (2009) Analysis of the substrate-binding site of human carbonyl reductases
CBR1 and CBR3 by site-directed mutagenesis. Chem Biol Interact 178:234–241.
Endo S, Matsunaga T, Kitade Y, Ohno S, Tajima K, El-Kabbani O, and Hara A (2008)
Human carbonyl reductase 4 is a mitochondrial NADPH-dependent quinone re-
ductase. Biochem Biophys Res Commun 377:1326–1330.
Fan L, Goh BC, Wong CI, Sukri N, Lim SE, Tan SH, Guo JY, Lim R, Yap HL, Khoo
YM, et al. (2008) Genotype of human carbonyl reductase CBR3 correlates with
doxorubicin disposition and toxicity. Pharmacogenet Genomics 18:621–631.
Fassas A and Anagnostopoulos A (2005) The use of liposomal daunorubicin
Mordente A, Meucci E, Martorana GE, Giardina B, and Minotti G (2001) Human
heart cytosolic reductases and anthracycline cardiotoxicity. IUBMB Life 52:83–88.
Oppermann U (2007) Carbonyl reductases: the complex relationships of mammalian
carbonyl- and quinone-reducing enzymes and their role in physiology. Annu Rev
Pharmacol Toxicol 47:293–322.
Plebuch M, Soldan M, Hungerer C, Koch L, and Maser E (2007) Increased resistance
of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline
inactivating enzymes. Cancer Lett 255:49–56.
Wirth H and Wermuth B (1992) Immunohistochemical localization of carbonyl
reductase in human tissues. J Histochem Cytochem 40:1857–1863.
Wojtacki J, Lewicka-Nowak E, and Le s´ niewski-Kmak K (2000) Anthracycline-
induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and
prevention—review of the literature. Med Sci Monit 6:411–420.
Zhang J and Blanco JG (2009) Identification of the promoter of human carbonyl
reductase 3 (CBR3) and impact of common promoter polymorphisms on hepatic
CBR3 mRNA expression. Pharmacol Res 26:2209–2215.
(
DaunoXome) in acute myeloid leukemia. Leuk Lymphoma 46:795–802.
Filling C, Berndt KD, Benach J, Knapp S, Prozorovski T, Nordling E, Ladenstein R,
J o¨ rnvall H, and Oppermann U (2002) Critical residues for structure and catalysis
in short-chain dehydrogenases/reductases. J Biol Chem 277:25677–25684.
Floyd JD, Nguyen DT, Lobins RL, Bashir Q, Doll DC, and Perry MC (2005) Cardio-
toxicity of cancer therapy. J Clin Oncol 23:7685–7696.
Forrest GL and Gonzalez B (2000) Carbonyl reductase. Chem Biol Interact 129:
21–40.
Gianni L, Salvatorelli E, and Minotti G (2007) Anthracycline cardiotoxicity in breast
cancer patients: synergism with trastuzumab and taxanes. Cardiovasc Toxicol
7:67–71.
Hoffmann F and Maser E (2007) Carbonyl reductases and pluripotent hydroxy-
steroid dehydrogenases of the short-chain dehydrogenase/reductase superfamily.
Drug Metab Rev 39:87–144.
Address correspondence to: Dr. K. Wayne Riggs, Division of Pharmaceutics
and Biopharmaceutics, Faculty of Pharmaceutical Sciences, University of Brit-
ish Columbia, 2146 East Mall, Vancouver, BC, Canada V6T 1Z3. E-mail:
Hunault-Berger M, Milpied N, Bernard M, Jouet JP, Delain M, Desablens B, Sadoun
A, Guilhot F, Casassus P, and Ifrah N (2001) Daunorubicin continuous infusion
induces more toxicity than bolus infusion in acute lymphoblastic leukemia induc-
tion regimen: a randomized study. Leukemia 15:898–902.